Ipsen (United Kingdom)

Recent papers from Ipsen (United Kingdom)

1. Elafibranor improves biochemical response and favorably modifies GLOBE and UK-PBC prognostic scores in primary biliary cholangitis: analyses from the phase III ELATIVE® trialBMC Gastroenterology · 2026
2. Treatment with elafibranor to normalize alkaline phosphatase in patients with primary biliary cholangitis and incomplete response to ursodeoxycholic acid: Results from the phase III randomized controlled ELSPIRE trialHepatology · 2026
3. Summary of Research: Two-Stage Estimation of Overall Survival in the Phase 3 CheckMate 9ER Trial, Adjusting for the Impact of Subsequent TherapyAdvances in Therapy · 2026
4. Clinical efficacy/effectiveness, safety, and health-related quality of life associated with relapsed/refractory pediatric low-grade glioma treatments: systematic literature reviewNeuro-Oncology Pediatrics · 2026
5. Indirect treatment comparison of odevixibat and maralixibat for the treatment of cholestatic pruritus in patients with Alagille syndromeJournal of Comparative Effectiveness Research · 2026
6. Response to Letter to the Editor: ‘NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial’ESMO Open · 2026
7. Development of the Fibrodysplasia Ossificans Progressiva FLare EXperience Revised (FOP-FLEX-R©) Questionnaire: A Patient-Reported Outcome MeasureBone · 2026
8. A Phase IV, Randomized, Double-Blind, Crossover Study to Compare the Clinical Safety and Efficacy of AbobotulinumtoxinA and OnabotulinumtoxinA in Adult Upper Limb SpasticityAdvances in Therapy · 2026
9. Abstract ND12: Development of IPN01203, a dual T cell agonist activating Vβ6/Vβ10 TCR-expressing T cellsCancer Research · 2026
10. Abstract Number: Esoc2026a1166 Persistence With Botulinum Toxin a and Factors Associated With Discontinuation in Patients With Stroke: A Retrospective Cohort StudyEuropean Stroke Journal · 2026
11. Abstract Number: Esoc2026a357 Sensitivity and Specificity of the Post-Stroke Spasticity Monitoring Questionnaire (Psmq) for Remote Monitoring of Spasticity Development: Interim Analysis From an Ongoing Epidemiological StudyEuropean Stroke Journal · 2026
12. Abstract CT087: Phase I/II FIH study of IPN60300, a first-in-class ADC targeting ITGA2, to assess the safety, tolerability, PK, biomarkers, immunogenicity and antitumor activity in adults with locally advanced solid tumorsCancer Research · 2026
13. Abstract 4444: Integrin alpha-2 (ITGA2) is a novel and well-suited antibody-drug conjugate (ADC) targetCancer Research · 2026
14. Abstract 1665: Preclinical characterization of IPN60300, a first-in-class ITGA2 antibody-drug conjugate for cancer therapyCancer Research · 2026
15. Botulinum toxin use in patients with neurological disorders: A U.S. ‐based claims database analysisPM&R · 2026
16. Impact of Early Versus Late Treatment with Botulinum Toxin A on Goal Attainment in Post-Stroke Spasticity: A Retrospective Cohort StudyToxins · 2026
17. Two-Stage Estimation of Overall Survival in the Phase 3 CheckMate 9ER Trial, Adjusting for the Impact of Subsequent TherapyOncology and Therapy · 2025
18. P31 Elafibranor impacts inflammatory, fibrotic and symptom-associated markers in patients with primary biliary cholangitis (PBC): proteomic results from the ELATIVE® trialBMJ · 2025
19. Ep10.01 Clinical Efficacy/Effectiveness, Safety and Health-Related Quality of Life Associated With Treatments for Relapsed/Refractory Paediatric Low-Grade Glioma: A Systematic Literature ReviewNeuro-Oncology · 2025
20. Impact of brain metastases on systemic renal cell carcinoma treatment outcomes: A systematic literature reviewCancer Treatment Reviews · 2025